Delphia Therapeutics

As the #biotech sector begins to stabilize after a challenging few years, companies are facing a unique landscape. Delphia CEO Kevin Marks looks forward to sharing his insight into "Building Biotechs to Last" during BioPharma Dive's Biotech's New Normal webinar next week. Register to listen in to Kevin and other industry leaders here: https://dive.pub/3CdaY17

At Delphia, we're pioneering a new category of cancer #genetics and therapeutic targets with the potential to develop better medicines for patients. These treatments have the potential to address significant cancer patient populations and disruptively shift how cancer is treated, ultimately leading to more sustained disease control and improved survival. Learn more about our next-generation #precisionmedicine approach on our website. https://lnkd.in/gY2bTe4R

Critical cellular pathways have multiple layers of regulation to ensure optimal activity. Oncogenic mutations enhance pathway activity and disrupt much of this regulation, leaving the remaining regulators vulnerable. Below, we outline how these key, vulnerable regulatory nodes present unique therapeutic targets to drive #overactivation and selectively degrade tumor cells using these approaches.

Delphia's approach begins with the identification of pathways that are vulnerable to overactivation. Our platform utilizes a combination of techniques to identify pathways with genetic evidence of #activationlethality. We then leverage functional genomics and other tools to identify regulatory weaknesses. Once we determine the most effective drugging strategy for targeting that node, we progress it into the lab to advance #drugdiscovery. Click below to learn more about this identification process.

For over 2 decades, cancer therapies have focused on inhibiting oncogenes. Yet many oncogenes are vulnerable not just to inhibition but also to activation – we call this surprising vulnerability ‘activation lethality.’ When oncogenes are overactivated, they overload cell stress pathways, and drugs that overactivate #cancer targets are selectively lethal to cancers with mutations that push them near the limits of tolerable pathway activity. Delphia’s approach integrates #tumor genetics, innovative functional genomic techniques, and studies on inhibitor drug resistance to identify targets that drive #activationlethality. You can learn more at https://lnkd.in/gY2bTe4R.

Cancer is a genetic disease, and the mutations in tumors have proven to be the best predictors of successful medicines. The landscape of #cancer mutations can be described by each mutation’s effect on the gene, and by whether that mutation is enriched in tumors or absent in tumors. To date, cancer treatment has focused on the first three quadrants of cancer genetics. In the coming weeks, we will highlight how Delphia is pioneering #drugdiscovery in the fourth (undrugged) quadrant: activation lethality.

We’re excited to share that Dr. Robert Abraham has joined Delphia as a Distinguished Fellow. Dr. Abraham will play a key role in advancing our research and pipeline progress as an embedded advisor to our team, working closely with our research and executive teams. Throughout his career in leadership roles at Pfizer, Vividion Therapeutics, and most recently, Odyssey Therapeutics, Dr. Abraham has been part of the development of more than 10 FDA-approved #oncology medicines.?We are thrilled to add his experience and expertise to our team. ? Dr. Abraham recently joined us in our Cambridge headquarters to connect with the Delphia team and share more about his experience in oncology drug development during a fireside chat with CEO Kevin Marks. We look forward to the impact he will have as we work to pioneer our next-generation precision medicine approach.

We’re honored to share that Delphia Therapeutics has been named as this year's #BiotechWeekBoston Boston Highlight winner. This award recognizes a Boston area company that has made a significant contribution to the biopharmaceutical industry over the past year, and we are thrilled to be recognized for our dedication to advancing a new #cancer treatment paradigm and improving the lives of patients in need. CEO Kevin Marks and members of the Delphia team were pleased to accept this award at last night's ceremony on behalf of our entire team. Congratulations to the many incredible companies who were nominated for this year's awards!

It is a privilege to be among the nominees for the Boston Highlight category for the upcoming 2024 #BiotechWeekBoston Awards. This category recognizes life-science organizations based in Boston that has made a significant contribution to the #biopharmaceutical industry over the past year. We extend our utmost gratitude to our Delphia team for their hard work and commitment to our mission. We look forward to joining the other finalists as the Biotech Week Boston Awards in September!

Last week, we were excited to commemorate two years since Delphia's inception, and the grand opening of our new office space. Our growth over the past two years has been remarkable, and the opening of our incredible new headquarters in One Kendall Square was the perfect way to mark the occasion. During our celebration, we partnered with the?Foundation for Hospital Art, a nonprofit?dedicated to involving patients and volunteers worldwide to create colorful, soothing artwork donated to hospitals to help soften the often stressful hospital experience. Team members were excited to put their personal touches on this meaningful?cause. We look forward to the?critical work ahead, making further progress for patients. Be sure to follow Delphia Therapeutics for ongoing updates and visit?delphiatx.com?to learn more.